Scientific Publications

June 30, 2023

Hawaii Global Summit for Thoracic Malignancies

Neoantigen-targeting TCR engineered cellular therapy for TP53, EGFR and RAS-mutant tumors

SUBJECT: TCR

June 3, 2023

American Society of Clinical Oncology (ASCO) 2023

Safety and Efficacy of Sleeping Beauty TCR-T Cells Targeting Shared KRAS and TP53 Mutations Expressed by Solid Tumors in First-in-Human Phase 1 Study

SUBJECT: TCR

November 10, 2022

Society for Immunotherapy of Cancer (SITC) 2022

hunTR®: a hyperplex platform for the discovery of neoantigen-reactive T-cell receptors

SUBJECT: TCR

September 30, 2022

CRI-ENCI-AACR (CICON22) Presentation by Dr. Marcelo Negrao

First two patients treated in TCR-T Library Phase 1/2 Trial had manageable safety profiles with no dose limiting toxicities; Patient 1 achieved a confirmed partial response, Patient 2’s achieved best overall response of stable disease

SUBJECT: TCR

September 21, 2022

Abstract: CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

First patient treated in TCR-T Library Phase ½ Trial achieved a confirmed partial response and Sleeping Beauty TCR-T cell therapy had a manageable safety profile with no dose limiting toxicities observed

SUBJECT: TCR

September 12, 2022

European Society of Medical Oncology (ESMO) 2022

Commencement of First-in-human Phase 1/2 TCR-T Clinical Trial Targeting Shared Tumor-specific Hotspot Mutations in Solid Tumors

SUBJECT: TCR

June 5, 2022

American Society of Clinical Oncology (ASCO) 2022

First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors

SUBJECT: TCR

May 16, 2022

American Society for Gene and Cell Therapy (ASGCT) 2022

Stem-cell memory TCR-T cells targeting hotspot EGFR, KRAS and p53 neoantigens generated through co-expression of membrane-bound Interleukin-15

SUBJECT: TCR

November 13, 2021

Society for Immunotherapy of Cancer (SITC) 2021

Neoantigen-specific TCR-T cells targeting shared hotspot mutations for adoptive cell therapy in common epithelial cancers.

SUBJECT: TCR

June 9, 2021

2021 Development of Sleeping Beauty Transposed TCR-T Cells for Adoptive Cell Therapy of Cancer

Drew Deniger, Vice President of Immunology, presentation at the Federation of American Societies for Experimental Biology (FASEB) virtual conference held on Wednesday June 9, 2021, entitled “Development of Sleeping Beauty Transposed TCR-T Cells for Adoptive Cell Therapy of Cancer”

SUBJECT: TCR

April 12, 2021

2021 Annual Meeting for American Association for Cancer Research (AACR)

Hotspot mutations in KRAS and TP53 targeted by TCR-T cells genetically modified with the Sleeping Beauty transposon/transposase system.

SUBJECT: TCR

December 8, 2019

61st American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando

Rapid Personalized Manufacture (RPM) of Sleeping Beauty System-generated NY-ESO-1-specific TCR-T Cells Co-expressing Membrane-bound IL-15 Yields Antitumor Responses

SUBJECT: TCR

June 16, 2016

The American Society of Gene & Cell Therapy

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System 

SUBJECT: TCR

Back to TOP